Core Viewpoint - The company reported a decline in total revenue for the first quarter of 2025, with specific segments showing varied performance, indicating challenges in the CDMO business while maintaining growth in CRO and other services [7][8]. Financial Performance - The company achieved total revenue of 52.84 million yuan, a decrease of 11.29% compared to the same period last year [7]. - Revenue from cell and gene therapy CRO services was 19.86 million yuan, reflecting a growth of 10.59% year-on-year [7]. - Revenue from cell and gene therapy CDMO services was 27.61 million yuan, down 27.74% year-on-year, primarily due to the types of CDMO orders executed and the progress of different projects [7]. - Other main business segments, including research reagents and cell storage services, generated revenue of 5.36 million yuan, an increase of 60.26% year-on-year [7]. Business Development - The company secured over 28 million yuan in new CDMO orders during the reporting period [7]. - It assisted clients in obtaining two IND approvals in the US and China, including one from the FDA, bringing the total to 46 approvals across multiple countries, with 13 from the FDA [7]. Intellectual Property - The company and its subsidiaries registered three new domestic trademarks and one copyright, and applied for two invention patents and six utility model patents during the reporting period [8]. - As of the end of the reporting period, the company held a total of 27 invention patents, 16 utility model patents, 2 design patents, 1 software copyright, 8 works copyrights, 65 domestic trademarks, and 4 international trademarks [8]. Share Buyback - On February 13, 2025, the company approved a share buyback plan to repurchase its A-shares using its own funds and a special loan for stock repurchase [9]. - As of April 10, 2025, the company completed the buyback of 18,726,690 shares, with a total expenditure of approximately 99.94 million yuan [10].

Core Viewpoint - The company is experiencing fluctuations in its CDMO business due to various factors, including market price sensitivity and increased operational costs, but it aims to enhance its market position and profitability through strategic initiatives and technological advancements [3][5][7]. Industry Overview - The domestic CGT (Cell and Gene Therapy) industry is supported by government policies and regulatory guidelines, leading to a gradual recovery in demand and supply dynamics. The industry is currently in a "supply clearing" phase, with expectations of improved market conditions as macroeconomic factors stabilize [2]. - The CGT sector saw a 4% year-on-year increase in financing events among Chinese CGT companies, indicating sustained long-term value recognition despite a cautious investment environment [2]. Company Performance - In 2024, the company reported a main revenue of 248 million yuan, a year-on-year increase of 21.16%, but faced a net loss of 322 million yuan, a decline of 151.54% [8]. - The company's CDMO business is impacted by a slowdown in investment in the biopharmaceutical sector, leading to increased price sensitivity among clients and fluctuating gross margins [3][8]. Business Segments - The company's CDMO business is focused on advanced therapies in cell and gene treatment, with a significant market potential. The company plans to optimize its operational model and enhance project delivery efficiency to improve gross margins over time [3][5]. - The CRO (Contract Research Organization) segment is experiencing steady growth, with a sales revenue of 85.82 million yuan in 2024, reflecting an 8.02% increase year-on-year. The client base has expanded to over 12,800 research laboratories [4][8]. Future Strategies - The company aims to strengthen its core technology in cell and gene therapy, expand its service offerings, and enhance its international market presence. It plans to leverage strategic partnerships and technological collaborations to explore new business opportunities [7]. - The establishment of a subsidiary focused on regenerative medicine marks a significant step in the company's strategic layout, aiming to address industry challenges and enhance its service capabilities in cell therapy [5][7]. Market Outlook - The Chinese stem cell market is projected to reach 26.5 billion yuan in 2024, with a year-on-year growth of 14%. However, the industry faces challenges such as intensified competition and varying product quality [5]. - The company anticipates a gradual recovery in industry conditions, driven by improved macroeconomic factors and supportive policies, which will enhance the overall market landscape for CGT [2].